We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide Group announces the exercise of the full over-allotment option
5 May 2021 - PolyPeptide Group AG ("PolyPeptide" or "the Group"), a global leader in peptide development and manufacturing, today announced that the Joint Global Coordinators have exercised in full the over-allotment option granted in connection with its Initial Public Offering (the "IPO") at the offer price of CHF 64 per share.
Read moreStock exchange listing
29 Apr 2021 - Today the PolyPeptide Group became a public company. Our shares are being traded on SIX, the Swiss Stock Exchange. What an exhilarating day! Today the PolyPeptide […]
Read morePolyPeptide News Flash, #3, 2020
17 Sep 2020 - The PolyPeptide Group is working on projects with clients developing peptide-based therapies and vaccines to combat COVID-19. As a Global Leader in Peptide Manufacturing and Development, […]
Read moreDesigning quality into therapeutic peptide manufacturing
1 Dec 2014 - The PolyPeptide Group has embraced quality by design and uses a risk based approach to develop, manufacture and commercialize peptide based therapeutics.[…]
Read moreThe future of peptide development in the pharmaceutical industry
2010 - Rodney Lax, PhD.; PharManufacturing: The International Peptide Review, Sep 2010 Read more
Read moreBuilding business in therapeutic peptides
2008 - Rodney Lax, PhD.; Sp2, Sep 2008 Read more
Read moreA peptide specialist
2005 - M. McCoy; Chemical & Engineering News, Jul 2005 Read more
Read more